DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SIMBRINZA

« Back to Dashboard

Clinical Trials for Simbrinza

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01937299	Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®	Completed	Alcon Research	Phase 4	The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy (TRAVATAN Z®).
NCT01937312	Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue	Completed	Alcon Research	Phase 4	The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy.
NCT01978600	Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension	Completed	Alcon Research	Phase 4	The purpose of this study is to evaluate intraocular pressure (IOP) over a 24-hour period using Simbrinza™ topical ophthalmic suspension.
NCT02167035	Comparison of Combigan BID Versus Simbrinza TID	Recruiting	Allergan	Phase 4	To compare Combigan BID vs Simbrinza TID in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.
NCT02167035	Comparison of Combigan BID Versus Simbrinza TID	Recruiting	Cornerstone Health Care, PA	Phase 4	To compare Combigan BID vs Simbrinza TID in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.

Clinical Trial Conditions for Simbrinza

Condition Name

Condition Name for Simbrinza
Intervention	Trials
Ocular Hypertension	6
Open-angle Glaucoma	3
Glaucoma	2
Open Angle Glaucoma	2

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Simbrinza
Intervention	Trials
Ocular Hypertension	6
Glaucoma, Open-Angle	5
Glaucoma	4
Hypertension	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Simbrinza

Trials by Country

Trials by Country for Simbrinza
Location	Trials
United States	4

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Simbrinza
Location	Trials
Texas	3
North Carolina	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Simbrinza

Clinical Trial Phase

Clinical Trial Phase for Simbrinza
Clinical Trial Phase	Trials
Phase 4	7

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Simbrinza
Clinical Trial Phase	Trials
Completed	3
Recruiting	3
Active, not recruiting	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Simbrinza

Sponsor Name

Sponsor Name for Simbrinza
Sponsor	Trials
Alcon Research	6
Cornerstone Health Care, PA	1
Allergan	1

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Simbrinza
Sponsor	Trials
Industry	7
Other	1

Export unavailable in trial.
Subscribe for complete access.